Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific wins “significant” patent battle

Boston Scientific wins “significant” patent battle

4th May 2006

Medical equipment manufacturer Boston Scientific claims to have won an important patent infringement suit in the Netherlands. The Dutch courts ruled that Sahajanand Medical Technologies’ Infinnium drug-eluting stent infringed on Boston Scientific and Angiotech Pharmaceuticals patents for the design of paclitaxel-eluting stents.

Sahajanand, which claims to be the world’s third-largest manufacturer of drug-eluting stents, will be banned from selling, importing, marketing or delivering Infinnium stents in the Netherlands. The Indian company will also have to pay Boston Scientific and Angiotech damages consisting of any profits made on the product, although Sahajanand may yet lodge an appeal.

Paul LaViolette, chief operating officer of Boston Scientific, said: “We are pleased the Dutch court upheld the validity of this important patent and found that it had been infringed.”

Angiotech’s president and chief operating officer, Dr William L. Hunter, added: “This is a significant victory in a key area of our intellectual property.”

In 2005, a Massachusetts Institute of Technology study estimated the drug-eluting stent market to be worth approximately $5 billion (2.7 billion pounds) and it said that Johnson and Johnson and Boston Scientific were the dominant companies in the market, with smaller companies like Medtronic also competing.

Drug-eluting stents have been developed during the last decade to solve the reduce the incidence of restenosis – the re-blocking of a vessel – that sometimes follows after angioplasties or the use of bare-metal stents.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.